Takeda announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes […]
Sleep Disorders
Inogen Launches Aurora CPAP Masks
Inogen, Inc. has announced the launch of Aurora CPAP masks, a new product in its expanding portfolio. Aurora’s introduction marks a significant milestone in Inogen’s strategy to expand its respiratory care portfolio and now bring quality, high-performing masks to patients indicated for obstructive sleep apnea (OSA). Strategic Positioning and Market […]
WAKIX Revenue to Exceed $1B in 2026, Orexin-2 Receptor Agonist in Pipeline
Harmony Biosciences, has announced strong preliminary, unaudited net product revenue for Q4 and full year 2025 of approximately $243 million and $868 million, respectively. The company continues to build on six consecutive years of revenue growth. On track to extend the pitolisant franchise, Harmony fortifies its profile as a profitable, […]
Daybreak Offers At-Home Dentist-Guided Model for Oral Appliances
A new Cedars Sinai Physician Associated Study is among the largest real-world evaluations of mandibular advancement device therapy for mild to moderate obstructive sleep apnea (OSA) and one of the first to examine a fully virtual, dentist-led care model from diagnosis through treatment and follow-up. Using the processes and care […]
FDA Clears Kricket Positive Airway Pressure Device with KPAP
SleepRes, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Kricket PAP device, powered by Kairos Positive Airway Pressure (KPAP)™ for the treatment of obstructive sleep apnea (OSA) in patients weighing more than 66 lbs. The SleepRes PAP system is intended for home, hospital/institutional, […]
A New Piece of the Puzzle
For the millions of people managing both obesity and obstructive sleep apnea (OSA), tirzepatide (Zepbound® and Mounjaro®, Eli Lilly and Co.) may offer a welcome approach to help reduce symptoms and improve overall health and quality of life. It’s been almost exactly a year since investigators of the SURMOUNT-OSA trial […]
Belun Introduces New Features & Innovations in Sleep Monitoring
Belun is excited to share some important updates to the Belun Sleep Platform, designed to bring more insights and improved interface for clinicians and researchers in sleep medicine. The latest update introduces trend-plotting capability for patient data, allowing you to: Track longitudinal changes in sleep and physiological data; Visualize patient treatment progress over time; Support clinical decision-making […]
Why Night Guards Aren’t Enough: Addressing the Neurological Roots of Sleep Bruxism with Biofeedback
For millions of people, the sound of teeth grinding is more than an annoyance—it’s a nightly neuromuscular storm. Sleep bruxism, characterized by involuntary clenching and grinding of the jaw during sleep, affects an estimated 8%–15% of adults worldwide.¹ Dentists have long turned to night guards as the standard solution, shielding […]
Hypoglossal Nerve Stimulation Patient Primer
There’s no one-size-fits-all approach for managing sleep apnea. Continuous positive airway pressure (CPAP) has been the go-to treatment for almost 40 years, but doctors have realized that some patients are not able to tolerate a CPAP mask or keep up with CPAP treatment over time. If you have a moderate […]
Inspire Medical Systems, Inc. Publishes Inspire V Data at ISSS/AAO-HNS Meetings
Inspire Medical Systems, Inc. published Inspire V clinical outcomes data from its Singapore clinical study, as well as the Company’s limited market release in the United States, including single-site experience at two leading centers. These data will be presented at the American Otolaryngology-Head and Neck Surgery (AAO-HNS) and International Surgical […]


















